Ionis Pharmaceuticals (IONS) Price & Analysis

Compare

1,463 Followers

IONS Stock Chart & Stats

$79.93

-$0.75(-2.14%)

At close: Jan 08 4:00 PM EST

$79.93

-$0.75(-2.14%)

Day’s Range― - ―

52-Week Range$23.95 - $83.61

Previous CloseN/A

Volume126.35K

Average Volume (3M)2.49M

Market Cap

$13.06B

Enterprise Value$12.98B

Total Cash (Recent Filing)$2.24B

Total Debt (Recent Filing)$1.49B

Price to Earnings (P/E)―

Beta0.77

Next Earnings

Feb 25, 2026

EPS Estimate

-1.31

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.80

Shares Outstanding161,974,400

10 Day Avg. Volume1,889,570

30 Day Avg. Volume2,492,326

Financial Highlights & Ratios

PEG Ratio-0.61

Price to Book (P/B)8.88

Price to Sales (P/S)7.41

P/FCF Ratio-9.57

Enterprise Value/Market Cap0.99

Enterprise Value/Revenue13.42

Enterprise Value/Gross Profit13.59

Enterprise Value/Ebitda-89.72

Forecast

1Y Price Target

$89.00

Price Target Upside11.35% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering16

EPS Forecast (FY)-2.3

Revenue Forecast (FY)$896.52M

Bulls Say, Bears Say

Bulls Say

Financial Growth2026 is set up to be an inflection point of growth for Ionis, driven by ongoing and expected launches of multiple wholly-owned products and supported by partnership revenue in diverse indications from Biogen and AstraZeneca and potentially from Novartis, GSK, and Roche.

Market DemandClinicians already treating FCS and high-risk sHTG patients are actively seeking access to olezarsen, indicating genuine pent-up demand and a favorable prescriber overlap.

Regulatory AdvancementsThe FDA’s Breakthrough Therapy Designation for olezarsen firms up regulatory posture by enabling rolling review and closer FDA engagement, which improves the commercial outlook.

Bears Say

Ionis Pharmaceuticals News

IONS, IBTA, IRDM: Cathie Wood Continues Trimming Stakes in Ionis, Ibotta, and Iridium Stocks

Cathie Wood made a few trades across ARK ETFs on Friday, December 19, 2025, based on the daily trade filings....

5d ago

IBTA

IONS

Ionis Pharmaceuticals price target raised to $95 from $82 at RBC Capital

RBC Capital analyst Luca Issi raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $95 from $82...

10d ago

IONS

Arrowhead price target raised to $100 from $70 at Piper Sandler

Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Arrowhead (ARWR) to $100 from $70 and...

10d ago

ARWR

IONS

Ionis Pharmaceuticals price target raised to $100 from $85 at Leerink

Leerink raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $100 from $85 and keeps an Outperform...

12d ago

ALNY

BBIO

Ionis Pharmaceuticals price target raised to $97 from $86 at BofA

BofA analyst Jason Gerberry raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $97 from $86 and...

18d ago

IONS

Ionis Pharmaceuticals gets Breakthrough Therapy designation for zilganersen

Ionis Pharmaceuticals (IONS) announced that the FDA has granted Breakthrough Therapy designation to zilganersen for the treatment of...

25d ago

IONS

Ionis Pharmaceuticals granted Breakthrough Therapy designation for olezarsen

Ionis Pharmaceuticals (IONS) announced that the FDA has granted Breakthrough Therapy designation to olezarsen as an adjunct to...

26d ago

IONS

Ionis Pharmaceuticals: Promising Growth Driven by Key Product Launches and Strategic Partnerships

TD Cowen analyst Yaron Werber has maintained their bullish stance on IONS stock, giving a Buy rating on...

24d ago

IONS

Arrowhead price target raised to $48 from $27 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Arrowhead (ARWR) to $48 from $27 but keeps a Neutral...

1M ago

ARWR

IONS

Ionis Pharmaceuticals Completes $770M Convertible Notes Offering

Ionis Pharmaceuticals ( ($IONS) ) has issued an update. On November 17, 2025, Ionis Pharmaceuticals completed a private...

1M ago

IONS

Ionis Pharmaceuticals announces CHMP opinion recommending Dawnzera approval

Ionis Pharmaceuticals (IONS) and Otsuka Pharmaceutical announced that the Committee for Medicinal Products for Human Use of the...

1M ago

IONS

Arrowhead price target raised to $45 from $29 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Arrowhead (ARWR) to $45 from $29 and keeps an Equal...

2M ago

ARWR

IONS

Ionis Pharmaceuticals announces $700M convertible senior notes offering

Ionis Pharmaceuticals (IONS) announced that it intends to offer, subject to market conditions and other factors, $700M aggregate...

2M ago

IONS

Ionis Pharmaceuticals’ Olezarsen: Promising Phase 3 Results and Blockbuster Potential Justify Buy Rating

Michael Ulz, an analyst from Morgan Stanley, reiterated the Buy rating on Ionis Pharmaceuticals. The associated price target...

2M ago

IONS

IONS FAQ

What was Ionis Pharmaceuticals Inc.’s price range in the past 12 months?

Ionis Pharmaceuticals Inc. lowest stock price was $23.95 and its highest was $83.61 in the past 12 months.

What is Ionis Pharmaceuticals Inc.’s market cap?

Ionis Pharmaceuticals Inc.’s market cap is $13.06B.

When is Ionis Pharmaceuticals Inc.’s upcoming earnings report date?

Ionis Pharmaceuticals Inc.’s upcoming earnings report date is Feb 25, 2026 which is in 60 days.

How were Ionis Pharmaceuticals Inc.’s earnings last quarter?

Ionis Pharmaceuticals Inc. released its earnings results on Oct 29, 2025. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$1.218 by $0.418.

Is Ionis Pharmaceuticals Inc. overvalued?

According to Wall Street analysts Ionis Pharmaceuticals Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ionis Pharmaceuticals Inc. pay dividends?

Ionis Pharmaceuticals Inc. does not currently pay dividends.

What is Ionis Pharmaceuticals Inc.’s EPS estimate?

Ionis Pharmaceuticals Inc.’s EPS estimate is -1.31.

How many shares outstanding does Ionis Pharmaceuticals Inc. have?

Ionis Pharmaceuticals Inc. has 161,974,400 shares outstanding.

What happened to Ionis Pharmaceuticals Inc.’s price movement after its last earnings report?

Ionis Pharmaceuticals Inc. reported an EPS of -$0.8 in its last earnings report, beating expectations of -$1.218. Following the earnings report the stock price went down -2.297%.

Which hedge fund is a major shareholder of Ionis Pharmaceuticals Inc.?

Currently, no hedge funds are holding shares in IONS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Ionis Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-39.99%

Trailing 12-Months

Asset Growth

-1.56%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Ionis Pharmaceuticals (IONS) Earnings & Revenues

Historic Earnings Reports

IONS Company Deck

IONS Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Ionis Pharmaceuticals demonstrated strong revenue growth and successful product launches, with significant advancements in their clinical pipeline. Despite these achievements, the company faces challenges with operating losses and patient identification for Tringolza. Overall, the positive developments outweigh the challenges.View all IONS earnings summaries

IONS Revenue Breakdown

60.82% R&D

39.18% Commercial

IONS Stock 12 Month Forecast

Average Price Target

$89.00

▲(11.35% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","111":"$111","47.25":"$47.3","68.5":"$68.5","89.75":"$89.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$89.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,47.25,68.5,89.75,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.99,84.14461538461538,86.29923076923076,88.45384615384614,90.60846153846154,92.76307692307692,94.9176923076923,97.07230769230769,99.22692307692307,101.38153846153847,103.53615384615384,105.69076923076923,107.84538461538462,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.99,82.52923076923076,83.06846153846153,83.6076923076923,84.14692307692307,84.68615384615384,85.22538461538461,85.76461538461538,86.30384615384615,86.84307692307692,87.38230769230769,87.92153846153846,88.46076923076923,{"y":89,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.99,80.68307692307692,79.37615384615384,78.06923076923077,76.76230769230769,75.45538461538462,74.14846153846153,72.84153846153846,71.53461538461538,70.22769230769231,68.92076923076922,67.61384615384615,66.30692307692307,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":36.1,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.03,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >